

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN- L85191DL2011PLC216530 GIN: U85191DL2011PLC216530

12th November, 2018

✓ The Secretary National Stock Exchange of India Ltd Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400051 Trading Symbol: AGLSL	~~The Secretary BSE Ltd Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001 Scrip Code: 540616~~
---	---

Sub: Outcome of the Board Meeting held on 12th November, 2018

Dear Sir/ Madam,

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that Board of Directors of the Company in their meeting held on 12th November, 2018 have inter alia approved the following:

1. On recommendation of the Audit Committee, the Board of Directors have approved un-audited financial results (standalone & consolidated) of the Company for the quarter and half year ending 30th September, 2018.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of duly signed un-audited financial results (standalone & consolidated), along with the Limited Review report by statutory auditor of the Company thereon, are attached herewith.


2. The Board of Directors have approved the continuation of Directorships of Mr. Onkar S. Kanwar as a Non- Executive Director, Dr. S. Narayan as a Non- Executive Independent Director and Mr. U.S. Anand as a Non- Executive Independent Director who have attained the age of 75 years, for seeking authorisation of Shareholders vide Special Resolution through Postal Ballot.
3. The Board of Directors have authorised Company Secretary to issue notice and to fix cutoff date for eligible shareholders to get notice of postal ballot and E-Voting. Accordingly, we shall communicate the same.

The Board Meeting commenced at 05:00 p.m. and concluded at 05:50 p.m.

Please take the above information on your records.

Thanking you
Yours Faithfully

For Artemis Global Life Sciences Limited



Anuj Sood
Company Secretary (A35276)
D-6/10, 3rd Floor, Rana Pratap Bagh
New Delhi-110007

ANAND DUA & ASSOCIATES

Chartered Accountants

Flat No 11, Pocket-7, Sector-12,
Dwarka, New Delhi-110 078
Email: anand.dua@gmail.com
Ph: 47021279


Review report

To
The Board of Directors
Artemis Global Life Sciences Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results (the Statement') of Artemis Global Life Sciences Limited ('the Company') for the half year ended 30th September 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05th July, 2016.
2. The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of Companies (Indian Accounting Standards) Rules 2015, as amended, and the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the company. Our responsibility is to issue a report on the statement based on our review
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the Company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as mentioned in paragraphs 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05' July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi
Date: 12/11/2018

For Anand Dua & Associates
Chartered Accountants
FRN: 04263N


(Anand Dua)
Partner
M.No. 083503

ANAND DUA & ASSOCIATES

Chartered Accountants

Flat No 11, Pocket-7, Sector-12,
Dwarka, New Delhi-110 078
Email: anand.dua@gmail.com
Ph: 47021279

Review report


To

The Board of Directors

Artemis Global Life Sciences Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results (the Statement') of Artemis Global Life Sciences Limited ('the Company') and its subsidiaries (the Company and its subsidiaries constitute 'the Group') for the half year ended 30th September 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05th July, 2016.
2. The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of Companies (Indian Accounting Standards) Rules 2015, as amended, and the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the company. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the Company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. We did not review the interim financial results of the subsidiaries included in the Statement whose interim financial results reflect the Group's share in the profit before tax is Rs 1619.25 lakhs for the half year ended 30th September 2018, and the Group's share in the profit after tax of Rs 1028.02 lakhs for the half year ended 30th September 2018 as considered in the Statement of the Group. These financial results have been reviewed by other auditors whose report has been furnished to us by the Management. Our report on the Statement of the Group, in so far as it related to the amounts and disclosures included in respect of the subsidiaries, is based solely on the reports of the other auditors.
5. Based on our review conducted as mentioned in paragraphs 3 and 4 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05' July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi
Date: 12/11/2018

For Anand Dua & Associates
Chartered Accountants
FRN: 04263N

(Anand Dua)
Partner
M.No. 083503

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CTN- L85191DL2011PLC216530 CIN- U85191DL2011PLC216530

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER, 30, 2018

(Rs. in Lakh)

S No.	Particulars	Quarter ended			Six Months ended		year ended
		30-Sep-18 (Unaudited)	30-Jun-18 (Unaudited)	30-Sep-17 (Unaudited)	30-Sep-18 (Unaudited)	30-Sep-17 (Unaudited)	31-Mar-18 (Audited)
1	Revenue from operations*	10.20	10.20	10.20	20.40	20.40	40.80
2	Other income	-	-	-	-	19.23	-
3	Total Income	10.20	10.20	10.20	20.40	39.63	40.80
	Expenses						
	Employee Benefits expenses	5.74	6.15	3.75	11.89	7.48	15.45
	Finance costs	-	-	-	-	-	-
	Depreciation and amortization expense	3.81	3.76	3.76	7.57	7.17	14.74
	Other expenses	14.75	8.23	8.94	22.98	18.94	37.43
4	Total expenses	24.30	18.14	16.46	42.44	33.59	67.62
5	Profit/(Loss) before Tax and exceptional items	(14.10)	(7.94)	(6.26)	(22.04)	6.04	(26.82)
6	Exceptional Items	-	-	11.38	-	11.38	10.99
7	Profit before tax	(14.10)	(7.94)	(17.64)	(22.04)	(5.34)	(37.81)
8	Tax Expense						
	Current Tax	-	-	(2.37)	-	-	2.99
	Deferred tax	(2.06)	(2.07)	0.57	(4.13)	1.52	(10.92)
	Total tax expense	(2.06)	(2.07)	(1.80)	(4.13)	1.52	(7.93)
9	Profit for the period	(12.04)	(5.87)	(15.84)	(17.91)	(6.87)	(29.88)
10	Other comprehensive income						
I	Items that will not be reclassified to profit or loss						
a	gains / (losses) on defined benefit plans	-	-	-	-	-	-
b	Deferred tax adjustment on revaluation	-	-	-	-	-	-
c	Income tax relating to items that will not be reclassified to profit & loss	-	-	-	-	-	-
II	Net other comprehensive income not to be reclassified to profit or loss in subsequent periods:	-	-	-	-	-	-
	Other comprehensive income for the period, net of income tax	-	-	-	-	-	-
11	Total comprehensive income/(loss) ('OCI')	(12.04)	(5.87)	(15.84)	(17.91)	(6.87)	(29.88)
12	Paid up equity share capital (Face value Rs. 2/- each)	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77
13	Other equity excluding revaluation reserve (as per balance sheet of previous accounting year)	**	**	**	**	**	14,529.92
14	Earning per share (Face value Rs. 2/- each) (refer note 7)						
	Basic (Rs.)	(0.02)	(0.01)	(0.02)	(0.03)	(0.01)	(0.05)
	Diluted (Rs.)	(0.02)	(0.01)	(0.02)	(0.03)	(0.01)	(0.05)

* Medical Equipment Lease rentals received from Artemis Medicare Services Ltd.

** Not required to be shown



Oh

Standalone Statement of Assets and Liabilities

(Rs. in lakh)

Particulars		As At Sep 30, 2018 (Unaudited)	As At March 31, 2018 (Audited)
(1)	Assets		
	Non-current assets		
	(a) Property, plant and equipment	169.79	177.36
	(b) Financial assets		
	i. Investments	15,990.62	15,990.62
	Total non-current assets (A)	16,160.41	16,167.98
(2)	Current assets		
	(a) Financial assets		
	i. Trade receivables	-	11.22
	ii. Cash and cash equivalents	1.78	8.87
	(b) Current tax assets (Net)	2.23	1.66
	(c) Other current assets	4.81	1.32
	Total current assets (B)	8.83	23.27
	Total Assets (A + B)	16,169.24	16,191.25
(3)	Equity and liabilities		
	Equity		
	(a) Equity share capital	1,323.77	1,323.77
	(b) Other equity		
	- Reserves & Surplus	14,512.01	14,529.92
	Total equity (C)	15,835.78	15,853.69
	Liabilities		
	Non-current liabilities		
	(a) Deferred tax liabilities	8.78	12.90
	Total non-current liabilities (D)	8.78	12.90
(4)	Current liabilities		
	(a) Provisions	0.94	1.02
	(a) Other current liabilities	323.73	323.64
	Total current liabilities (E)	324.68	324.66
	Total liabilities (F) = (D + E)	333.46	337.56
	Total equity and liabilities (C + F)	16,169.24	16,191.25



Handwritten signature/initials

Notes

1. The above results for the quarter/ half year ended September 30, 2018 were reviewed by the Audit Committee & approved by the Board of Directors at its meeting held on November 12th, 2018. The statutory auditors have expressed unmodified opinion on the aforesaid results.

2. Adoption of Ind AS 115-Revenue from contracts with customers

The Ministry of Corporate affairs (MCA), on March 20th, 2018 notified Ind AS 115 "Revenue from Contracts with Customers" as part of Companies (Indian Accounting Standards) Amendment Rules 2018. The new standard is effective from April 1, 2018. The adoption of Ind AS - 115 by the company effective 1st April, 2018 has no significant impact on the financial results for the quarter/ half ended 30th September, 2018.

3. The Company's operation predominantly comprise of only one segment - income from lease of medical equipments to Artemis Medicare Services Ltd. and therefore the figures shown above relate to that segment.


4. The Company and its subsidiary company i.e. Artemis Health Sciences Ltd and its step subsidiary companies i.e. Athena Eduspark Limited and Artemis Medicare Services Limited have decided to merge and the proposed Composite Scheme of Amalgamation between the aforesaid Companies and their respective shareholders and creditors under section 230 to 232 and other applicable provisions of Companies Act, have been approved in the meeting of the Board of Directors held on 09th May, 2018 and this is subject to clearance by National Company Law Tribunal & other regulatory approvals.

5. The above financial results have been prepared in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under 133 of the companies act 2013, and the other recognised accounting practices and policies to the extent applicable.

6. EPS is not annualised for the quarter/ half year ended September 30, 2018 & September 30, 2017 and quarter ended June 30, 2018.

7. Previous period figures have been regrouped / reclassified wherever necessary to correspond with the current period classification / disclosures.

For and on behalf of the Board of Directors of
ARTEMIS GLOBAL LIFE SCIENCES LIMITED



ONKAR S. KANWAR
CHAIRMAN



PLACE: GURUGRAM
DATE: NOVEMBER 12, 2018

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN- L85191DL2011PLC216530

GIN: U85191DL2011PLC216530

STATEMENT OF UNAUDITED CONSOLIDATED RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPT 30, 2018.

(Rs. in Lakh)

S No.	Particulars	Artemis Global Life Sciences Ltd					
		Quarter ended			Six Months ended		Year ended
		30-Sep-18	30-Jun-18	30-Sep-17	30-Sep-18	30-Sep-17	31-Mar-18
		(Unaudited)	(Unaudited)	(Not Subjected Limited Review)	(Unaudited)	(Not Subjected Limited Review)	(Audited)
1	Revenue from operations (Net off inter company transaction)	14,088.99	12,643.07	12,621.52	26,732.06	24,551.78	50,278.71
2	Other income	89.48	116.86	138.99	206.34	251.84	429.90
3	Total Income	14,178.46	12,759.94	12,760.51	26,938.40	24,803.62	50,708.61
	Expenses						
	Purchases of pharmacy drugs & medical consumables	3,321.06	2,991.29	2,907.78	6,312.35	6,352.36	12,083.89
	Purchases of Stock in Trade	48.00	28.62	20.88	76.62	67.23	137.15
	Changes in inventories of pharmacy drugs, Medical consumables & Stock in Trade	(80.24)	10.66	248.67	(69.58)	(260.59)	(8.31)
	Employee benefit expenses	2,336.67	2,356.49	2,175.98	4,693.16	4,415.43	9,068.74
	Finance Cost (Net off inter company transaction)	298.94	202.94	262.23	501.88	469.03	942.03
	Depreciation and amortization expense	495.58	490.25	493.70	985.83	979.18	1,880.56
	Other expenses	6,757.29	6,083.66	6,033.40	12,840.95	11,694.05	23,103.62
4	Total expenses	13,177.28	12,163.92	12,142.64	25,341.20	23,666.69	47,207.18
5	Profit before exceptional items and tax	1,001.18	596.02	617.87	1,597.20	1,136.93	3,501.42
6	Exceptional items	-	-	11.38	-	11.38	10.99
7	Profit before Tax	1,001.18	596.02	606.49	1,597.20	1,125.55	3,490.43
8	Tax Expense						
	Current Tax	448.17	259.14	136.25	707.31	252.08	656.31
	Deferred Tax	(81.56)	(28.55)	97.53	(110.11)	176.48	206.49
	Total Tax Expense	366.61	230.59	233.78	597.20	428.56	862.80
9	Profit for the period	634.57	365.43	372.70	1,000.00	696.98	2,627.63
10	Other comprehensive income						
	Items that will not be reclassified to profit or loss						
a	Gains / (losses) on defined benefit plans	(0.94)	(4.39)	(4.17)	(5.33)	(8.34)	(17.56)
b	Deferred tax adjustment on revaluation	6.77	6.78	-	13.55	-	14.30
c	Income tax relating to items that will not be reclassified to profit & loss	0.33	1.53	1.45	1.86	2.91	6.14
ii	Net other comprehensive income not to be reclassified to profit or loss in subsequent periods:	6.17	3.92	(2.72)	10.09	(5.43)	2.88
	Other comprehensive income for the period, net of income tax	6.17	3.92	(2.72)	10.09	(5.43)	2.88
11	Total comprehensive income/(loss) ("OCI")	640.74	369.35	369.99	1,010.09	691.56	2,630.50
12	Paid up equity share capital (Face value Rs. 10/- each)	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77	1,323.77
13	Other equity excluding revaluation reserves (as per balance sheet of previous accounting year)	**	**	**	**	**	19,442.49
14	Earning per share (Face value Rs. 10/- each) (refer note 7)						
	Basic (Rs.)	0.96*	0.55*	0.56*	1.51*	1.05*	3.97*
	Diluted (Rs.)	0.96	0.55	0.56	1.51	1.05	3.97

** Not required to be shown



Handwritten signature or initials.

Consolidated Statement of Assets and Liabilities

(Rs. in Lakh)

Particulars	As At 30th Sept, 2018 (Unaudited)	As At 31st March, 2018 (Audited)
Assets		
Non-current assets		
Property, plant and equipment	33,707.38	30,736.33
Capital work-in-progress	4,681.91	4,317.46
Goodwill	4,162.07	4,162.07
Other intangible assets	279.01	292.85
Financial assets		
i. Loans	106.89	173.96
ii. Other financial assets	55.96	29.51
Non-current tax assets (Net)	654.65	390.85
Other non-current assets	356.45	714.22
Total non-current assets	44,006.31	40,817.25
Current assets		
Inventories	720.40	644.80
Financial assets		
i. Trade receivables	6,479.76	5,567.42
ii. Cash and cash equivalents	302.88	394.00
iii. Bank balances other than (ii) above	600.06	948.16
iv. Loans	215.89	100.80
v. Other financial assets	464.47	499.52
Current tax assets (Net)	17.07	16.67
Other current assets	754.46	724.70
Total current assets	9,555.00	8,896.07
Total Assets	53,561.32	49,713.32
Equity and liabilities		
Equity		
Equity share capital	1,323.77	1,323.77
Other equity	26,993.27	25,983.18
Total equity	28,317.04	27,306.96
Liabilities		
Non-current liabilities		
Financial liabilities		
i. Borrowings	5,107.11	5,224.61
Provisions	393.21	359.84
Deferred tax liabilities (Net)	1,975.64	1,760.10
Total non-current liabilities	7,475.96	7,344.55
Current liabilities		
Financial liabilities		
i. Borrowings		
i. Trade payables	7,805.81	6,730.71
ii. Other financial liabilities	6,012.64	3,915.96
Provisions	1,090.79	1,079.34
Other current liabilities	2,859.08	3,335.80
Total current liabilities	17,768.32	15,061.81
Total liabilities	25,244.28	22,406.36
Total equity and liabilities	53,561.32	49,713.32



or

Notes

1. The above results for the quarter / half year ended September 30, 2018 were reviewed by the Audit Committee & approved by the Board of Directors at its meeting held on November 12th, 2018. The statutory auditors have expressed unmodified opinion on the aforesaid results.

2. Adoption of Ind AS 115- "Revenue from Contracts with Customers"

The Ministry of Corporate Affairs (MCA), on March 20th, 2018 notified Ind AS 115 "Revenue from Contracts with Customers" as part of Companies (Indian Accounting Standards) Amendment Rules 2018. The new standard is effective from April 1, 2018. The adoption of Ind AS - 115 by the company effective 1st April, 2018 has no significant impact on the financial results for the quarter/half year ended 30th September, 2018.

3. Segment Reporting

Business segment

The company's operation predominantly comprise of only one business segment- Income from Healthcare services.

Geographical information

Geographical information analyses the company's revenue by the Company's country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been based on the geographical location of the customers.

Region	Quarter ended			Six Months ended		Year ended
	30-Sep-18	30-Jun-18	30-Sep-17	30-Sep-18	30-Sep-17	31-Mar-18
India	8,255.33	7,760.80	8,045.47	16,016.13	15,698.06	32,366.33
Outside India	5,833.65	4,882.27	4,576.05	10,715.92	8,852.15	17,910.80
Total	14,088.98	12,643.07	12,621.52	26,732.05	24,550.21	50,277.13

Region	Carrying amount of Segment assets	
	30-Sep-18	31-Mar-18
India	39,510.48	36,275.14
Outside India	-	-
Total	39,510.48	36,275.14

4. The Company and its subsidiary company i.e. Artemis Health Sciences Ltd and its step subsidiary companies i.e. Athena Eduspark Limited and Artemis Medicare Services Limited have decided to merge and the proposed Composite Scheme of Amalgamation between the aforesaid Companies and their respective shareholders and creditors under section 230 to 237 and other applicable provisions of Companies Act 2013, have been approved in the meeting of the Board of Directors held on 09th May, 2018 and this is subject to clearance by National Company Law Tribunal & other regulatory approvals.

5. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.

6. Results for the quarter & half year ended 30th September 2018 have been subjected to limited review by the auditors. The Ind AS compliant corresponding figures and half year ended 30th September 2017 were not subject to limited review.

7. EPS is not annualised for the quarter/ half year ended September 30, 2018 & September 30, 2017 and quarter ended June 30, 2018.

8. Previous period figures have been regrouped / reclassified wherever necessary to correspond with the current period classification / disclosures.



For and on behalf of the Board of Directors of
ARTEMIS GLOBAL LIFE SCIENCES LIMITED

Onkar S. Kanwar
ONKAR S. KANWAR
CHAIRMAN

PLACE: GURUGRAM
DATE: NOVEMBER 12, 2018